International Stem Cell Corp. (ISCO) Advances Parkinson’s Disease Clinical Trials in Australia
California-based International Stem Cell Corporation this morning announced that its wholly owned subsidiary, Cyto Therapeutics, has signed a Letter of Intent (LOI) with Royal Melbourne Hospital in Australia to conduct phase I/IIa clinical trials of ISCO's proprietary human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson's Disease. The LOI follows a recent meeting with Australian Therapeutics Goods Administration (TGA), and precedes a full agreement expected to be signed after TGA and the HREC approve the clinical protocol for the trials. "We had a productive meeting with TGA where we discussed the clinical protocol and potentially came to an…